New Drug RLF-100 Reveals Dramatic Outcomes for Vital Covid-19 Patients

on
Representative image.

Representative image.

Aviptadil is a formula of Vasoactive Digestive Polypeptide (VIP), which is present in high concentrations in the lungs and known to obstruct various inflammatory cytokines.

  • PTI

    • .

  • Last Updated: August 6, 2020, 9: 56 AM IST

Share this:

The drug has been authorized by the FDA for emergency use at numerous clinical sites in clients who are too ill to enter the FDA’s Stage 2/3 trials.

According to a statement from the drug maker NeuroRX, independent researchers have actually reported that aviptadil obstructed replication of the SARS coronavirus in human lung cells and monocytes.

The drug appeared to have rapidly cleared pneumonitis findings on an X-ray, enhanced blood oxygen and a 50 per cent or greater average decrease in lab markers associated with COVID-19 inflammation, the statement said.

Learn More

https://covid19globalcases.com/new-drug-rlf-100-reveals-dramatic-outcomes-for-vital-covid-19-patients/